Bromocriptine

Generic Name
Bromocriptine
Brand Names
Cycloset, Parlodel
Drug Type
Small Molecule
Chemical Formula
C32H40BrN5O5
CAS Number
25614-03-3
Unique Ingredient Identifier
3A64E3G5ZO
Background

Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptin...

Indication

For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodop...

Associated Conditions
Acromegaly, Hyperprolactinemia, Parkinson's Disease (PD), Type 2 Diabetes Mellitus, Neuroleptic malignant syndrome (NMS)
Associated Therapies
-

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

First Posted Date
2022-01-06
Last Posted Date
2024-08-07
Lead Sponsor
Dennis M. McNamara, MD, MS
Target Recruit Count
250
Registration Number
NCT05180773
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 54 locations

Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease

First Posted Date
2020-06-02
Last Posted Date
2022-04-07
Lead Sponsor
Kyoto University
Target Recruit Count
8
Registration Number
NCT04413344
Locations
🇯🇵

Asakayama Hospital, Sakai, Osaka, Japan

🇯🇵

Tokushima University Hospital, Tokushima, Japan

🇯🇵

Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan

and more 5 locations

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

First Posted Date
2020-04-17
Last Posted Date
2020-04-17
Lead Sponsor
Ganin Fertility Center
Target Recruit Count
107
Registration Number
NCT04351126
Locations
🇪🇬

Ganin Fertility Center, Cairo, Maadi, Egypt

Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

Early Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2019-10-16
Last Posted Date
2024-10-08
Lead Sponsor
University of California, San Diego
Target Recruit Count
31
Registration Number
NCT04128683
Locations
🇺🇸

University of California San Diego, San Diego, California, United States

Satisfaction of Patients With the Chosen Method of Inhibition of Lactation

First Posted Date
2019-07-31
Last Posted Date
2019-07-31
Lead Sponsor
Żelazna Medical Centre, LLC
Target Recruit Count
90
Registration Number
NCT04038749
Locations
🇵🇱

Żelazna Medical Centre, Warsaw, Poland

Bromocriptine for Patients with Schizophrenia and Prediabetes

Phase 4
Not yet recruiting
Conditions
Interventions
First Posted Date
2018-07-02
Last Posted Date
2024-11-14
Lead Sponsor
VA Pittsburgh Healthcare System
Target Recruit Count
15
Registration Number
NCT03575000
Locations
🇺🇸

VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States

Dopamine Action on Metabolism in Relation to Genotype

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2018-05-15
Last Posted Date
2024-02-02
Lead Sponsor
University Hospital Tuebingen
Target Recruit Count
150
Registration Number
NCT03525002
Locations
🇩🇪

University of Tuebingen, Department of Internal Medicine IV, Tübingen, Germany

🇩🇪

University Hospital Cologne, Cologne, Germany

🇩🇪

University Hospital Luebeck, Luebeck, Germany

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

Phase 4
Withdrawn
Conditions
Interventions
First Posted Date
2016-10-11
Last Posted Date
2021-11-16
Lead Sponsor
University of California, Berkeley
Registration Number
NCT02929485
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

University of California, Berkeley, Berkeley, California, United States

Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome

First Posted Date
2016-07-27
Last Posted Date
2016-07-27
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
200
Registration Number
NCT02846493
Locations
🇨🇳

The Sixth Affiliated Hospital,Sun Yat-Sen University, Guangzhou, Guangdong, China

Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

Phase 4
Completed
Conditions
Interventions
First Posted Date
2016-02-17
Last Posted Date
2021-12-10
Lead Sponsor
Eastern Virginia Medical School
Target Recruit Count
84
Registration Number
NCT02682901
Locations
🇺🇸

Eastern Virgnia Medical School, Strelitz Diabetes Center, Norfolk, Virginia, United States

© Copyright 2024. All Rights Reserved by MedPath